<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690323</url>
  </required_header>
  <id_info>
    <org_study_id>NL50467.018.14</org_study_id>
    <nct_id>NCT03690323</nct_id>
  </id_info>
  <brief_title>Pancreatic Locally Advanced Irresectable Cancer Ablation</brief_title>
  <acronym>PELICAN</acronym>
  <official_title>Pancreatic Locally Advanced Irresectable Cancer Ablation; a Randomized Controlled Superiority Phase III Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comprehensive Cancer Centre The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Olympus</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the PELICAN trial is to investigate the survival benefit of RFA plus standard&#xD;
      palliative chemotherapy as compared to palliative chemotherapy alone in patients with LAPC&#xD;
      after 2 months of induction chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is the fifth leading cause of cancer-related death in the Netherlands. Each&#xD;
      year around 900 patients in the Netherlands are diagnosed with irresectable locally advanced&#xD;
      pancreatic cancer (LAPC), which has a median survival of 7.9 months. Standard treatment is&#xD;
      palliative chemotherapy, which offers only a very limited survival benefit. Radiofrequency&#xD;
      ablation (RFA) is a new ablative technique for LAPC, which is feasible and safe and has been&#xD;
      suggested to improve survival. A randomized controlled trial has not yet been performed.&#xD;
&#xD;
      The aim of the PELICAN trial is to investigate the survival benefit of RFA plus standard&#xD;
      palliative chemotherapy as compared to palliative chemotherapy alone in patients with LAPC&#xD;
      after 2 months of induction chemotherapy. In a randomized controlled parallel-group&#xD;
      superiority multicenter phase III clinical trial.&#xD;
&#xD;
      The intervention will be RFA followed by chemotherapy (gemcitabine monotherapy,&#xD;
      nab-paclitaxel plus gemcitabine or FOLFIRINOX). The comparison will be standard palliative&#xD;
      treatment consisting of gemcitabine monotherapy, nab-gemcitabine plus gemcitabine or&#xD;
      FOLFIRINOX Primary endpoint: Overall survival. Secondary endpoints: Progression free&#xD;
      survival, complications, pain, radiological tumor response, CA-19.9 and CEA response, quality&#xD;
      of life, immunomodulation and total direct and indirect costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 7, 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Radiofrequency ablation (RFA) plus chemotherapy versus chemotherapy monotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1.5 years</time_frame>
    <description>The period of time between randomization and death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1.5 years</time_frame>
    <description>The period of time between randomization and disease progression or death (by any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1.5 years</time_frame>
    <description>The occurence of any post-operative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological tumor response</measure>
    <time_frame>1.5 years</time_frame>
    <description>The radiologic tumor response between start of study treatment till end of follow up (or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor marker response</measure>
    <time_frame>1.5 years</time_frame>
    <description>The response of the tumor marker between start of study treatment till end of follow up (or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire</measure>
    <time_frame>1.5 years</time_frame>
    <description>The quality of life measured between start study treatment till end of follow up (or death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Locally Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RFA: laparotomy is performed followed by radiofrequency ablation of the tumor.&#xD;
After recovery of the RFA patients will continue chemotherapy:&#xD;
FOLFIRINOX or nab-paclitaxel + gemcitabine or gemcitabine monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will continue chemotherapy:&#xD;
FOLFIRINOX or nab-paclitaxel plus gemcitabine or gemcitabine monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation (RFA)</intervention_name>
    <description>RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.</description>
    <arm_group_label>RFA</arm_group_label>
    <other_name>Celon ProSurge bipolar probe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <description>Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel plus Gemcitabine</intervention_name>
    <description>Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
          2. Locally irresectable tumor&#xD;
&#xD;
          3. Primary tumor&#xD;
&#xD;
          4. Stable disease or partial response after 2 months of induction chemotherapy (according&#xD;
             to RECIST)&#xD;
&#xD;
          5. Fit for chemotherapy as assessed by the medical oncologist, plus:&#xD;
&#xD;
               -  Absolute neutrophil count: 1.5 × 109/L&#xD;
&#xD;
               -  Platelet count: 100 × 109/L&#xD;
&#xD;
               -  Renal function: creatinine clearance&gt; 50 ml/min&#xD;
&#xD;
               -  Transaminases ≤ 3 x ULN&#xD;
&#xD;
          6. Fit for surgery assessed by the treating surgeon and anesthesiologist&#xD;
&#xD;
          7. RFA technical feasible&#xD;
&#xD;
          8. Written informed consent&#xD;
&#xD;
          9. Age ≥ 18 years&#xD;
&#xD;
         10. Expert panel approval for randomisation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. WHO performance status ≥ 3&#xD;
&#xD;
          2. Distant metastases on abdominal or thoracic CT scan*&#xD;
&#xD;
          3. Previous surgical, local ablative or radiotherapy for pancreatic cancer or&#xD;
             chemotherapy which is inconsistent with the prescribed induction schedule according to&#xD;
             protocol**&#xD;
&#xD;
          4. Stenosis of &gt; 50% of the hepatic artery AND stenosis of &gt;50% of the portal vein/&#xD;
             superior mesenteric vein&#xD;
&#xD;
          5. Second primary malignancy, except adequately treated non-melanoma skin cancer, in situ&#xD;
             carcinoma of the cervix uteri or other malignancies treated at least 5 years&#xD;
             previously without signs of recurrence.&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
               -  Positive regional lymph nodes metastases are not a reason for exclusion. Lymph&#xD;
                  nodes are considered as regional, according to the consensus statement by the&#xD;
                  International Study Group of Pancreatic Surgery (ISGPS). Suspicious lymph nodes&#xD;
                  only on radiologic basis are not considered as metastasis. Only when suspicion is&#xD;
                  high due to large infiltration, pathological examination by FNA can be&#xD;
                  considered.&#xD;
&#xD;
                    -  Surgical exploration is not a contra-indication for inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>IQ Molenaar, Prof. Dr.</last_name>
    <phone>0031683904242</phone>
    <email>pelican@dpcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MGH Besselink, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionaal Academisch Kankercentrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IQ Molenaar, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>I.Q. Molenaar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Pancreatic neoplasms</keyword>
  <keyword>Locally advanced pancreatic cancer</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

